Lantheus Holdings, Inc. (LNTH) stock analysis
LNTH · Lantheus Holdings, Inc.
Latest recorded price: USD 101.72
Model-estimated fair value: USD 152.74. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic
At $101.72, LNTH trades 33.4% below the model's base-case value of $152.74. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $114.84 in the conservative case and $198.53 in the optimistic case, with a valuation confidence score of 55/100. About 71% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 18.1%, free cash flow margin 23.0%, ROIC 25.1%. The model flags 1 risk signal for this company.
Similar companies in Healthcare
- Liquidia Corporation (LQDA)
- Neurocrine Biosciences, Inc. - Common Stock (NBIX)
- Phibro Animal Health Corporation (PAHC)
- Prestige Consumer Healthcare Inc. (PBH)
- Pacira BioSciences, Inc. (PCRX)
- Perrigo Company plc (PRGO)
- Supernus, Inc. - Common Stock (SUPN)
- Teva Pharmaceutical Industries Limited Ordinary Shares (TEVA)